This trial is active, not recruiting.

Condition sarcoma
Treatments dna methylation analysis, rna analysis, comparative genomic hybridization, gene expression analysis, microarray analysis, mutation analysis, laboratory biomarker analysis
Sponsor Children's Oncology Group
Collaborator National Cancer Institute (NCI)
Start date August 2010
End date January 2100
Trial size 200 participants
Trial identifier NCT01190943, AOST10B5, COG-AOST10B5, NCI-2011-02840


RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.

PURPOSE: This research study is studying DNA biomarkers in tissue samples from patients with osteosarcoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective retrospective

Primary Outcomes

Identification and validation of biomarkers with potential clinical utility
time frame:

Eligibility Criteria

Male or female participants up to 120 years old.

DISEASE CHARACTERISTICS: - Diagnosis of osteosarcoma - Fresh-frozen samples collected at the time of diagnosis with matched blood DNA (preferred) from patients enrolled on the following osteosarcoma biology protocols: - COG-P9851 - COG-AOST06B1 - Available clinical outcome data PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified

Additional Information

Official title Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma
Principal investigator Ching C. Lau, MD, PhD
Description OBJECTIVES: - To comprehensively detect genomic, epigenomic, and transcriptomic aberrations in tissue samples from patients with osteosarcoma that may play a role in chemoresistance and metastasis using high-resolution genome-wide technologies. - To identify recurrent genetic mutations involved in the pathogenesis of osteosarcoma, especially for the development of chemoresistance and metastatic tumors. - To identify and validate these biomarkers for new therapeutic targets for patients with osteosarcoma, especially those with metastatic disease and whose tumors are resistant to standard chemotherapy. OUTLINE: This is a multicenter study. Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Children's Oncology Group.